MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:34Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Thiazolidinediones]]
			[[Category:Antihyperglycemic agents]]
			[[Category:PPAR gamma agonists]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #133

2026-05-23T03:51:56Z

parser-claude batch MedTemplate pre-fill, Top 300 #133

New page

{{MedTemplate
| generic = Pioglitazone
| brand = Actos
| structure =
| classes = [[:Category:Thiazolidinediones|Thiazolidinedione (TZD)]], [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]], [[:Category:PPAR_gamma_agonists|PPAR-γ agonist]]
| uses = <vote slug="type2-diabetes-use">Type 2 diabetes mellitus</vote>, <vote slug="nash-mash-use">NASH/MASH (off-label, with insulin resistance phenotype)</vote>
| starting_dose = 15-30 mg PO once daily; titrate to 45 mg
| preparations = 15, 30, 45 mg tablets
| fda_max = 45 mg/d
| pill_id =
| routes = Oral
| onset = HbA1c effect at 12-16 weeks (slower than other classes)
| duration = 24 hours
| halflife = ~3-7 hours (parent); 16-24 hours including active metabolites<ref name="actos-label">FDA Prescribing Information, Actos (pioglitazone HCl), Takeda, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s055lbl.pdf</ref>
| bioavailability = High (oral; absorption not affected by food)<ref name="actos-label" />
| pregnancy = Limited data; switch to insulin where feasible.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for heart failure (do not initiate in NYHA III/IV; can precipitate or worsen HF in any patient)<ref name="actos-label" />
| mechanism = <vote slug="pioglitazone-mech-claim">Pioglitazone is a selective agonist of peroxisome proliferator-activated receptor γ (PPAR-γ); the activated receptor remodels transcription of adipocyte differentiation, lipid storage, and insulin-sensitivity genes, lowering insulin resistance with effects on free fatty acid handling, adiponectin secretion, and inflammatory tone.</vote> Mechanism is insulin-sensitizing rather than insulin-secretagogue, so monotherapy hypoglycemia risk is low. Characteristic adverse effects: fluid retention (HF precipitation), weight gain, distal bone fracture risk (especially in women), and a small bladder cancer signal historically debated; benefit in NASH/MASH and the IRIS trial's stroke recurrence benefit in insulin-resistant non-diabetics keep pioglitazone clinically interesting<ref name="actos-label" />.
}}

== References ==
<references />

Pioglitazone - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #133